Merck Licenses SciBrunch's SPR2015 for $2.13 Billion

Merck has entered into an exclusive global license agreement with SciBrunch Therapeutics Co., Ltd. for SPR2015, a preclinical oral KRAS G12D inhibitor.

The deal includes an upfront payment of $400 million and potential milestone payments worth up to $1.73 billion, totaling $2.13 billion in aggregate value.

MERCK () will record a pre-tax charge of $400 million related to this transaction in the third quarter of 2026.

Sr. VP George Addona said the agreement complements Merck's expanding pipeline of precision targeted candidates with SPR2015, a potent engineered inhibitor for one of the most prevalent mutant forms of KRAS found in human cancers.